Pancreatic Cancer


Relevance: Medium
Most relevant for: People with previously treated advanced pancreatic cancer
Update: FDA grants expanded access to an investigational drug for pancreatic cancer
The U.S. Food and Drug Administration (FDA) granted expanded access to the investigational drug daraxonrasib for people with previously treated pancreatic cancer. This allows more access to the drug outside of a clinical trial, even though it has not yet been approved by the FDA. (posted 5/29/2026)
READ MORE ›

Relevance: High
Most relevant for: People interested in cancer survivorship
Topic: Gastrointestinal cancer survivorship in younger adults includes challenges often overlooked
This review summarizes a presentation given at the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. The presenter discussed survivorship concerns that younger adults with gastrointestinal (GI) cancer say their doctors often overlook. (posted 4/17/2026)
READ MORE ›

Relevance: High
Most relevant for: People with a PALB2 mutation
Study: Understanding inherited PALB2 mutations and risk of multiple cancers
Inherited mutations in the PALB2 gene are linked to increased risk of several cancers, including breast, pancreatic, ovarian, and prostate cancers. This study estimates the effect of an inherited PALB2 mutation on a person’s risk of developing each of these cancers. (posted 4/6/2026)
READ MORE ›

Relevance: Medium
Most relevant for: People with Lynch syndrome
Study: Early trial of new vaccine shows promise for people with Lynch syndrome
The Nous-209 vaccine for preventing cancer in people with Lynch syndrome was tested in an early-phase study. The safety and immune response results were encouraging. An immune response was seen in most participants, suggesting that the vaccine may help reduce the chance of developing cancer in people with Lynch syndrome. (posted 3/23/2026)
READ MORE ›

Relevance: High
Most relevant for: People who are experiencing pelvic side effects related to treatment or surgery
Article: Pelvic health therapy improves quality of life after treatment or prevention
Pelvic health therapy can significantly improve comfort, function and quality of life for people experiencing pelvic pain, bladder or bowel issues, and sexual dysfunction after cancer treatment or preventive surgery. This article highlights the importance of restoring tissue mobility, strengthening the pelvic floor and providing emotional support to empower survivors and previvors. (posted 3/23/2026)
READ MORE ›

Relevance: High
Most relevant for: People diagnosed with cancer who require 5-FU or capecitabine treatment
Guideline: FDA recommends testing to prevent serious side effects from 5-FU and capecitabine chemotherapy
A small number of people treated with the chemotherapy drugs 5-FU (5-fluorouracil) or capecitabine (Xeloda) can have serious or even life-threatening side effects because their body breaks down the drug more slowly than is typical. A genetic test called DPYD testing can help identify people at higher risk for serious side effects before treatment starts. (posted 2/11/26)
READ MORE ›

Relevance: Medium-High
Most relevant for: People who have had or are considering liquid biopsy testing
Topic: What Patients Need to Know About Liquid Biopsies in Cancer Care
Liquid biopsies are tests that look for signs of cancer in blood or other body fluids. These signs can include cancer cells that have broken away from a tumor, pieces of cancer cell DNA and proteins or other biomarkers found in cancer cells. Liquid biopsies can be used to screen for cancer before a cancer diagnosis or guide treatment after a diagnosis. (posted 2/6/26)
READ MORE ›

Relevance: High
Most relevant for: Men and women diagnosed with breast cancer who have a BRCA1 or BRCA2 mutation
Study: Understanding the risks of a second cancer after a breast cancer diagnosis in people with BRCA1 and BRCA2 mutations
After breast cancer, people who have a BRCA1 or BRCA2 mutation face a greater risk of a second cancer compared to individuals without a BRCA mutation. This study helps to better understand this risk so that breast cancer survivors with mutations can receive informed, personalized plans for surveillance and follow-up care. (Posted 12/11/25)
READ MORE ›

Relevance: Medium-High
Most relevant for: People with a high risk for pancreatic or colon cancer
Study: Early trial of new vaccine shows promise for treating KRAS-mutated pancreatic and colon cancers
A vaccine for treating pancreatic and colon cancers with a biomarker known as a KRAS mutation produced a strong immune response in people at high risk of recurrence in an early clinical trial. This promising vaccine is now being studied in a larger clinical trial. (Posted 12/9/25)
Este artículo está disponible en español
READ MORE ›

Relevance: Medium
Most relevant for: People concerned about their risk of pancreatic cancer
Study: Bacteria and fungi in the mouth may help identify those at risk for pancreatic cancer
Pancreatic cancer often grows quickly and is usually discovered at a later stage. A better understanding of risk factors, like changes in bacteria found in the mouth, could provide doctors with early warning signs needed to help them diagnose and treat cancer sooner. The results of this study suggest that changes in bacteria and fungi in your mouth may help identify people who are at higher risk of pancreatic cancer. (Posted 11/24/25)
READ MORE ›